Hikma 'sixth largest US generics firm' following Roxane buy from Boehringer
This article was originally published in Scrip
Hot on the heels of Teva's acquisition of Allergan's generics business, Hikma Pharmaceuticals has agreed to buy US generics firm Roxane Laboratories from Boehringer Ingelheim in a deal worth around $2.65bn, making Hikma "the sixth largest generics company" by revenue in the US. "The US generics market is currently a very attractive place to be," Hikma's CEO Said Darwazah told Scrip. "If you want to grow fast, there is no other market that can provide you with this kind of opportunity."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.